Opendata, web and dolomites

FAST-BM

FAST-BM: FibroSelect: delivering A Step-change in Biotherapeutic Manufacturing

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FAST-BM project word cloud

Explore the words cloud of the FAST-BM project. It provides you a very rough idea of what is the project "FAST-BM" about.

ameliorated    functionalised    fit    eases    700k    pound    cagr    purifying    productivity    pipeline    requirement    operate    manufacturing    medium    biopharma    drugs    flexibility    manner    single    helps    point    payers    varying    287    expended    seven    fibroselect    antibodies    global    gt    platforms    maximising    billion    purification    drug    facility    flexible    bispecific    latter    constraints    capture    spending    puridify    innovative    demand    manufactured    7m    medicines    cope    wholly    platform    batch    biotherapeutics    accounting    price    therapeutic    manufacture    reductions    disposable    50    25    prior    moving    cellulose    70       complexity    serves    fusion    columns    chromatography    sensitivity    2020    market    validating    biotherapeutic    re    diversity    cleaning    potentially    economic    vectors    formats    industry    utilisation    area    viral    thereby    rapid    biosimilar    ligand    proteins    bioprocessing    technologies    chromatographic    innovation    limitation    worldwide    drive   

Project "FAST-BM" data sheet

The following table provides information about the project.

Coordinator
PURIDIFY LTD 

Organization address
address: STEVENAGE BIOSCIENCE CATALYST GUNNELS WOOD ROAD
city: STEVENAGE
postcode: SG1 2FX
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.puridify.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-08-01   to  2016-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PURIDIFY LTD UK (STEVENAGE) coordinator 50˙000.00

Map

 Project objective

Seven of the top 10 global medicines by spending are biotherapeutics drugs, and the market is growing at a CAGR of 10.1% to reach a value of $287 billion in 2020.

Challenges facing biotherapeutic manufacture are: i) Chromatographic purification, accounting for >50% of processing costs. This is important given the increasing price sensitivity of payers worldwide and serves as a limitation to the growth of the biosimilar industry; ii) Increasing diversity and complexity of biotherapeutics: ~70% of biopharma’s product pipeline are large complex proteins (e.g. bispecific antibodies, fusion proteins or viral vectors), which offer promising therapeutic opportunities, but cannot be manufactured cost effectively as they do not fit with current bioprocessing platform technologies; iii) Process flexibility: The rapidly evolving industry is moving to more flexible disposable formats to cope with uncertainty in drug development and varying market demand.

Puridify has developed an innovative bioprocessing platform technology, FibroSelect, a functionalised cellulose chromatography medium to enable high-productivity, product capture and purification that is economic to operate in a disposable manner.

FibroSelect addresses each point above by i) enabling cost reductions of up to 25% (potentially £700K - £2.7m per batch); ii) offering flexibility to design new bioprocessing platforms; iii) being a wholly disposable system where all purifying ligand is expended per-batch purification. It is innovation in the latter area that helps to drive costs down and increase productivity, as the requirement for cleaning columns and re-validating prior to purification of the next batch of biotherapeutic product is ameliorated. FibroSelect eases process constraints and enables flexibility through single-use processing opportunities thereby maximising facility utilisation as has been seen with the rapid growth in use of single-use technologies for manufacturing.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FAST-BM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FAST-BM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More